Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib

Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synerg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Discov
Main Authors: Xia, Hongping, Lee, Kee Wah, Chen, Jianxiang, Kong, Shik Nie, Sekar, Karthik, Deivasigamani, Amudha, Seshachalam, Veerabrahma Pratap, Goh, Brian Kim Poh, Ooi, London Lucien, Hui, Kam M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592242/
https://ncbi.nlm.nih.gov/pubmed/28900541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddiscovery.2017.58
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados